GNPX News and Press, Genprex Inc. From 12/14/22

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer PR Newswire Recommendation to Advance to Increased Dose in Third a...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will present at the upcoming RHK 2022 Disruptive Growth Conference taking place at the offices of Reed Smith in New York Cit...

Genprex to Present at Upcoming December Investor Conference PR Newswire Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN , Texas , Dec. 2, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has announced the lineup of conferences it will be attending in October. The company will also be participating in these events, with its corpo...

Genprex to Present at Upcoming October Investor and Industry Conferences PR Newswire Corporate and Clinical Presentations to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Oct. 7, 2022 /PRNewswire/ -- Genprex, Inc. ...

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its Chief Financial Officer Ryan Confer will be providing a virtual overview of Genprex’s gene thera...

Genprex to Present at Upcoming September Investor Conference PR Newswire Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Sept. 8, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Co...

Gainers: Artelo Biosciences ( ARTL ) +31% . Ventyx Biosciences ( VTYX ) +23% . Eargo ( EAR ) +19% . Fulcrum Therapeutics ( FULC ) +18% . Genprex ( GNPX ) +17% . Losers: Albireo Pharma ( ALBO ) -25% . Sema4...

Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers PR Newswire Provides Protection for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial AUSTIN, Texas , ...

Gainers: Viridian Therapeutics VRDN +45% . TherapeuticsMD TXMD +21% . Unity Biotechnology UBX +21% . Brainstorm Cell Therapeutics BCLI +12% . Genprex GNPX +10% . Losers: IDEAYA Biosciences IDYA -33% . Apexigen ( APGN ) -15%...